SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Trace Neuroscience, Inc., a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases, today announced the initiation of its global clinical development program for TRCN-1023, an investigational antisense oligonucleotide (ASO) designed to restore UNC13A protein function for the treatment of amyotrophic lateral sclerosis (ALS). The global TRCN-1023 clinical program includes the Phase 1/2 FUN